ReviewDrug design, development and therapy2026
Baicalin as a Multifunctional Regulator of Gut Health: Integrative Mechanisms Involving Inflammation, Barrier Integrity, and Gut-Organ Axis.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Baicalin alleviates Trueperella pyogenes-induced endometritis with associated changes in gut microbiota composition.BMC veterinary research · 2026Article
- Bile Acids and the Gut-X Axis: TCM-Mediated Systemic Protection and Therapeutic Opportunities for Multi-Organ Diseases.Metabolites · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intestinal health is sustained by coordinated control of mucosal immunity, epithelial barrier integrity, and the gut microbiota and its metabolites. Disruption of these tightly coupled systems contributes to a wide spectrum of disorders, ranging from infectious enteritis and inflammatory bowel disease (IBD) to ischemia-reperfusion injury and metabolic dysfunction with extra-intestinal sequelae. Baicalin (BAI), a major flavonoid from Scutellaria baicalensis, has emerged as a multi-level regulator of gut homeostasis. Across diverse preclinical models, BAI attenuates inflammatory signaling and frequently converges on NF-κB-centered networks; it also rebalances immune responses by modulating macrophage polarization and T-cell subsets, limits oxidative and ferroptotic damage through cytoprotective programs, and restores barrier function by preserving tight junctions and mucus-layer defenses. In parallel, BAI remodels microbial community structure and microbial metabolites, including short-chain fatty acids and bile-acid signaling, providing a plausible basis for benefits along gut-organ axes such as the gut-liver and gut-metabolic axes. This review integrates mechanistic evidence across these three pillars and highlights key translational gaps, including limited oral bioavailability, incomplete causal validation of proposed targets, and the need to disentangle BAI from active metabolites. We further discuss derivative design, formulation, and combination strategies to improve exposure and accelerate clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.